Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Clin Pharmacol Ther. 2012 Dec 5;93(1):33–35. doi: 10.1038/clpt.2012.196

Figure 1.

Figure 1

Illustrated is a conceptual diagram highlighting the different mechanisms of testing for actionable pharmacogenomic variants and their implementation into routine clinical practice. Notable are the turnaround times for each testing scenario and the need for clinical decision support when deploying pre-emptive genetic testing. TAT: turnaround time.